Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BMY Stock Forecast 2026-2027
$59.08
Current Price
$120.31B
Market Cap
Buy 10
Hold 18
Sell 1
Wall St Analyst Ratings
Distance to BMY Price Targets
+26.9%
To High Target of $75.00
+8.3%
To Median Target of $64.00
-32.3%
To Low Target of $40.00
BMY Price Momentum
-2.0%
1 Week Change
-2.7%
1 Month Change
+0.1%
1 Year Change
+9.5%
Year-to-Date Change
-6.1%
From 52W High of $62.89
+38.9%
From 52W Low of $42.52
📊 TOP ANALYST CALLS
Did BMY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bristol-Myers is one of their latest high-conviction picks.
Latest BMY Stock Price Targets & Analyst Predictions
Based on our analysis of 38 Wall Street analysts, BMY has a neutral consensus with a median price target of $64.00 (ranging from $40.00 to $75.00). The overall analyst rating is Buy (7.0/10). Currently trading at $59.08, the median forecast implies a 8.3% upside. This outlook is supported by 10 Buy, 18 Hold, and 1 Sell ratings.
The most optimistic forecast comes from David Amsellem at Piper Sandler, projecting a 26.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BMY Analyst Ratings
10
Buy
18
Hold
1
Sell
BMY Price Target Range
Low
$40.00
Average
$64.00
High
$75.00
Current: $59.08
Latest BMY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BMY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 25, 2026 | RBC Capital | Trung Huynh | Sector Perform | Initiates | $60.00 |
| Feb 23, 2026 | Piper Sandler | David Amsellem | Overweight | Maintains | $75.00 |
| Feb 20, 2026 | Barclays | Emily Field | Overweight | Initiates | $75.00 |
| Feb 6, 2026 | Guggenheim | Seamus Fernandez | Buy | Maintains | $72.00 |
| Feb 6, 2026 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $60.00 |
| Feb 6, 2026 | Citigroup | Geoff Meacham | Neutral | Maintains | $64.00 |
| Jan 28, 2026 | Piper Sandler | David Amsellem | Overweight | Maintains | $66.00 |
| Jan 27, 2026 | Citigroup | Andrew Baum | Neutral | Maintains | $60.00 |
| Jan 13, 2026 | Leerink Partners | David Risinger | Outperform | Maintains | $60.00 |
| Jan 9, 2026 | Scotiabank | Louise Chen | Sector Perform | Maintains | $60.00 |
| Jan 7, 2026 | UBS | Michael Yee | Buy | Upgrade | $65.00 |
| Jan 7, 2026 | Citigroup | Andrew Baum | Neutral | Maintains | $53.00 |
| Dec 15, 2025 | B of A Securities | Tim Anderson | Buy | Upgrade | $61.00 |
| Dec 12, 2025 | Guggenheim | Seamus Fernandez | Buy | Upgrade | $62.00 |
| Dec 12, 2025 | Morgan Stanley | Terence Flynn | Underweight | Maintains | $37.00 |
| Dec 10, 2025 | Wells Fargo | Mohit Bansal | Equal-Weight | Maintains | $55.00 |
| Dec 4, 2025 | Scotiabank | Louise Chen | Sector Perform | Maintains | $53.00 |
| Dec 2, 2025 | Goldman Sachs | Asad Haider | Neutral | Maintains | $57.00 |
| Nov 17, 2025 | Citigroup | Andrew Baum | Neutral | Maintains | $45.00 |
| Aug 1, 2025 | Citigroup | Andrew Baum | Neutral | Maintains | $47.00 |
Bristol-Myers Squibb Company (BMY) Competitors
The following stocks are similar to Bristol-Myers based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BMY
Bristol-Myers
mkt cap
120.31B
Bristol-Myers Squibb Company (BMY) Financial Data
Bristol-Myers Squibb Company has a market capitalization of $120.31B with a P/E ratio of 17.0x. The company generates $48.19B in trailing twelve-month revenue with a 14.6% profit margin.
Revenue growth is +1.3% quarter-over-quarter, while maintaining an operating margin of +28.2% and return on equity of +40.4%.
Valuation Metrics
Market Cap
$120.31B
Enterprise Value
$156.60B
P/E Ratio
17.0x
PEG Ratio
0.0x
Price/Sales
2.5x
Growth & Margins
Revenue Growth (YoY)
+1.3%
Gross Margin
+67.2%
Operating Margin
+28.2%
Net Margin
+14.6%
EPS Growth
+1,409.7%
Financial Health
Cash/Price Ratio
+8.9%
Current Ratio
1.3x
Debt/Equity
255.0x
ROE
+40.4%
ROA
+10.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bristol-Myers Squibb Company (BMY) Business Model
About Bristol-Myers Squibb Company
What They Do
Global biopharmaceutical firm focused on innovative medicines.
Business Model
The company discovers, develops, and sells medications targeting critical therapeutic areas such as oncology and immunology. It generates revenue through the sales of its key products, including Eliquis and Opdivo, which address significant health challenges and have a strong market presence.
Additional Information
Bristol-Myers Squibb, founded in 1887, has approximately 34,100 employees and is headquartered in New York. The company reported trailing twelve-month revenues of US$48.03 billion and earnings of US$6.04 billion, demonstrating strong financial health with robust gross margins and the ability to pay dividends.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
32,500
CEO
Dr. Christopher S. Boerner Ph.D.
Country
United States
IPO Year
1972
Website
www.bms.comBristol-Myers Squibb Company (BMY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ImmunityBio Valuation: Paying 33x Sales for Anktiva
IBRX stock surge has pushed valuation to ~33x sales as Anktiva adoption accelerates - but the premium assumes flawless commercialization and expansion.
Mar 13, 2026
By Sundeep Ganoria
Analyst Blog
IBRX Stock: Anktiva's Approvals and What Comes Next
ImmunityBio's Anktiva drives revenue surge and new approvals, as U.S. uptake and global launches set up a pivotal 2026.
Mar 13, 2026
By Sundeep Ganoria
Analyst Blog
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Gilead plans a $7.8B Arcellx acquisition as cell therapy sales decline, seeking full control of anito-cel to strengthen its oncology pipeline.
Mar 13, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
BMY reports positive phase III SUCCESSOR-2 results showing that mezigdomide combination therapy improves progression-free survival in relapsed multiple myeloma, enhancing its CELMoD program.
Why It Matters
Positive phase III results for mezigdomide enhance BMY's pipeline, suggesting potential for increased revenue and market share in cancer treatment, which may attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
BMY has a robust pipeline with several late-stage candidates and anticipates registrational data by 2026, boosting confidence in its CELMoD program.
Why It Matters
BMY's robust late-stage pipeline and upcoming data boosts confidence in its CELMoD program, suggesting potential future revenue growth and strengthening its market position.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Pfizer provides the highest dividend yield for new investors, while Dentsply Sirona is expected to deliver the fastest dividend growth.
Why It Matters
Pfizer's high dividend yield attracts income-focused investors, while Dentsply Sirona's potential for rapid dividend growth appeals to those seeking capital appreciation.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
The company’s growth portfolio is compensating for declines in legacy treatments, with notable advancements in two developmental programs.
Why It Matters
The growth portfolio's success and advancements in developmental programs indicate potential future revenue, mitigating concerns over legacy treatment declines, which can boost investor confidence.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Bristol Myers (BMY) is currently attracting significant attention from Zacks.com users, indicating potential interest in the stock's future performance.
Why It Matters
Increased interest in Bristol Myers may indicate potential stock price movements, influenced by investors' perceptions and upcoming developments affecting the company's prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Bristol Myers has received FDA approval to expand the use of Sotyktu for psoriatic arthritis, following positive results from the POETYK study.
Why It Matters
Bristol Myers gaining FDA approval for Sotyktu boosts its market potential and revenue streams, enhancing investor confidence in the company's growth prospects.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About BMY Stock
What is Bristol-Myers Squibb Company's (BMY) stock forecast for 2026?
Based on our analysis of 38 Wall Street analysts, Bristol-Myers Squibb Company (BMY) has a median price target of $64.00. The highest price target is $75.00 and the lowest is $40.00.
Is BMY stock a good investment in 2026?
According to current analyst ratings, BMY has 10 Buy ratings, 18 Hold ratings, and 1 Sell ratings. The stock is currently trading at $59.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BMY stock?
Wall Street analysts predict BMY stock could reach $64.00 in the next 12 months. This represents a 8.3% increase from the current price of $59.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bristol-Myers Squibb Company's business model?
The company discovers, develops, and sells medications targeting critical therapeutic areas such as oncology and immunology. It generates revenue through the sales of its key products, including Eliquis and Opdivo, which address significant health challenges and have a strong market presence.
What is the highest forecasted price for BMY Bristol-Myers Squibb Company?
The highest price target for BMY is $75.00 from David Amsellem at Piper Sandler, which represents a 26.9% increase from the current price of $59.08.
What is the lowest forecasted price for BMY Bristol-Myers Squibb Company?
Price targets from Wall Street analysts for BMY are not currently available. The stock is trading at $59.08.
What is the overall BMY consensus from analysts for Bristol-Myers Squibb Company?
The overall analyst consensus for BMY is neutral. Out of 38 Wall Street analysts, 10 rate it as Buy, 18 as Hold, and 1 as Sell, with a median price target of $64.00.
How accurate are BMY stock price projections?
Stock price projections, including those for Bristol-Myers Squibb Company, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 10:45 AM UTC